{"filing":{"accession_number":"0001171843-26-005577","cik":"0001828253","ticker":"EVAX","company_name":"Evaxion A/S","form":"6-K","filing_date":"2026-08-17","report_date":"2026-08-17","primary_document":"f6k_081726.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1828253/000117184326005577/f6k_081726.htm"},"events":[{"id":28116,"run_id":25698,"accession_number":"0001171843-26-005577","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"This press release announces a material pipeline expansion and refocus: the addition of EVX-05, a new glioblastoma vaccine program developed in collaboration with Duke University, and the discontinuation of the EVX-03 program. While the company characterizes this as \"portfolio management,\" the launch of a new clinical-stage program targeting a high-mortality cancer with significant unmet medical need, combined with an academic partnership for clinical testing, represents a material operational and strategic shift that would affect a reasonable investor's assessment of the company's R\u0026D direction and competitive positioning.","company_name":"Evaxion A/S","ticker":"EVAX","filing_date":"2026-08-17","form":"6-K","submitted_at":null,"items":[{"id":29926,"accession_number":"0001171843-26-005577","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces a material pipeline expansion and refocus: the addition of EVX-05, a new glioblastoma vaccine program developed in collaboration with Duke University, and the discontinuation of the EVX-03 program. While the company characterizes this as \"portfolio management,\" the launch of a new clinical-stage program targeting a high-mortality cancer with significant unmet medical need, combined with an academic partnership for clinical testing, represents a material operational and strategic shift that would affect a reasonable investor's assessment of the company's R\u0026D direction and competitive positioning.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-17T12:05:38.237713+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29926,"accession_number":"0001171843-26-005577","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces a material pipeline expansion and refocus: the addition of EVX-05, a new glioblastoma vaccine program developed in collaboration with Duke University, and the discontinuation of the EVX-03 program. While the company characterizes this as \"portfolio management,\" the launch of a new clinical-stage program targeting a high-mortality cancer with significant unmet medical need, combined with an academic partnership for clinical testing, represents a material operational and strategic shift that would affect a reasonable investor's assessment of the company's R\u0026D direction and competitive positioning.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-17T12:05:38.237713+00:00","company_name":"Evaxion A/S","ticker":"EVAX","filing_date":"2026-08-17"}]}